{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T04:02:48Z","timestamp":1747454568853,"version":"3.40.5"},"reference-count":26,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Heart failure with reduced ejection fraction is a syndrome consisting of symptoms (dyspnoea, fatigue, swelling) and\/or signs of congestion (pulmonary crackles, oedema). It is caused by structural and\/or functional pathologies, most commonly ischaemic heart disease, entailing elevated cardiac filling pressures and can result in low cardiac output. Medical treatment has evolved during the recent decades as outlined in this review, and a 4-pillar treatment strategy is recommended including a renin-angiotensin-aldosterone system blocker or sacubitril\/valsartan, a betablocker, a mineralocorticoid antagonist, and an SGLT2 inhibitor.<\/jats:p>","DOI":"10.61409\/v05240339","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T13:46:53Z","timestamp":1730900813000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Aetiology and treatment of chronic heart failure with reduced left ventricular function"],"prefix":"10.61409","author":[{"given":"Anders Hostrup","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine Kiilerich","family":"Lauridsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Vishram-Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Vase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Vraa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil","family":"Wolsk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Barasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle","family":"S\u00f8holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia Paarup","family":"Dridi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Mamas MA, Sperrin M, Watson MC et al. Do patients have worse outcomes in heart failure than in cancer? Eur J Heart Fail. 2017;19(9):1095-1104. https:\/\/doi.org\/10.1002\/ejhf.822","DOI":"10.1002\/ejhf.822"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail. 2022;24(1):4-131. https:\/\/doi.org\/10.1002\/ejhf.2333","DOI":"10.1002\/ejhf.2333"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"McMurray JJ. Improving outcomes in heart failure: a personal perspective. Eur Heart J. 2015;36(48):3467-3470. https:\/\/doi.org\/10.1093\/eurheartj\/ehv565","DOI":"10.1093\/eurheartj\/ehv565"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314(24):1547-1552. https:\/\/doi.org\/10.1056\/NEJM198606123142404","DOI":"10.1056\/NEJM198606123142404"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-2057. https:\/\/doi.org\/10.1056\/NEJMoa042934","DOI":"10.1056\/NEJMoa042934"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Wiggers H, K\u00f8ber L, Gislason G et al. The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 \u00d7 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J. 2021;231:137-146. https:\/\/doi.org\/10.1016\/j.ahj.2020.09.020","DOI":"10.1016\/j.ahj.2020.09.020"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316(23):1429-1435. https:\/\/doi.org\/10.1056\/NEJM198706043162301","DOI":"10.1056\/NEJM198706043162301"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Eichhorn EJ, Domanski MJ, Krause-Steinrauf H et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659-1667. https:\/\/doi.org\/10.1056\/NEJM200105313442202","DOI":"10.1056\/NEJM200105313442202"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","DOI":"10.1056\/NEJMoa1409077"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","DOI":"10.1056\/NEJMoa1911303"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Packer M, Anker SD, Butler J et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","DOI":"10.1056\/NEJMoa2022190"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-533. https:\/\/doi.org\/10.1056\/NEJM199702203360801","DOI":"10.1056\/NEJM199702203360801"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Abdin A, Bauersachs J, Soltani S et al. A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction. ESC Heart Fail. 2023;10(1):24-31. https:\/\/doi.org\/10.1002\/ehf2.14197","DOI":"10.1002\/ehf2.14197"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Miller RJH, Howlett JG, Fine NM. A novel approach to medical management of heart failure with reduced ejection fraction. Can J Cardiol. 2021;37(4):632-643. https:\/\/doi.org\/10.1016\/j.cjca.2020.12.028","DOI":"10.1016\/j.cjca.2020.12.028"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Marti CN, Fonarow GC, Anker SD et al. Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. Eur J Heart Fail. 2019;21(3):286-296. https:\/\/doi.org\/10.1002\/ejhf.1351","DOI":"10.1002\/ejhf.1351"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Velazquez EJ, Lee KL, Deja MA et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607-1616. https:\/\/doi.org\/10.1056\/NEJMoa1100356","DOI":"10.1056\/NEJMoa1100356"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Brembilla-Perrot B, Ferreira JP, Manenti V et al. Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation. Eur J Heart Fail. 2016;18(4):394-401. https:\/\/doi.org\/10.1002\/ejhf.482","DOI":"10.1002\/ejhf.482"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Yarlagadda RK, Iwai S, Stein KM et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation. 2005;112(8):1092-1097. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.546432","DOI":"10.1161\/CIRCULATIONAHA.105.546432"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Hasdemir C, Yuksel A, Camli D et al. Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias. Pacing Clin Electrophysiol. 2012;35(4):465-470. https:\/\/doi.org\/10.1111\/j.1540-8159.2011.03324.x","DOI":"10.1111\/j.1540-8159.2011.03324.x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Arbelo E, Protonotarios A, Gimeno JR et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. https:\/\/doi.org\/10.1093\/eurheartj\/ehac262","DOI":"10.1093\/eurheartj\/ehac262"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"K\u00f8ber L, J.J. Thune JJ, Nielsen JC et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-1230. https:\/\/doi.org\/10.1056\/NEJMoa1608029","DOI":"10.1056\/NEJMoa1608029"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Connolly SJ, Hallstrom AP, Cappato R et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21(24):2071-2078. https:\/\/doi.org\/10.1053\/euhj.2000.2476","DOI":"10.1053\/euhj.2000.2476"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-1549. https:\/\/doi.org\/10.1056\/NEJMoa050496","DOI":"10.1056\/NEJMoa050496"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:59:13Z","timestamp":1747378753000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V05240339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":26,"URL":"https:\/\/doi.org\/10.61409\/v05240339","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}